Cargando…

Using Misoprostol for Primary versus Secondary Prevention of Postpartum Haemorrhage – Do Costs Matter?

BACKGROUND: Postpartum heammorrhage (PPH), defined as blood loss greater than or equal to 500 ml within 24 hours after birth, is the leading cause of maternal deaths globally and in India. Misoprostol is an important option for PPH management in setting where oxytocin (the gold standard for PPH prev...

Descripción completa

Detalles Bibliográficos
Autores principales: Chatterjee, Susmita, Sarkar, Anupam, Rao, Krishna D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5068696/
https://www.ncbi.nlm.nih.gov/pubmed/27755601
http://dx.doi.org/10.1371/journal.pone.0164718
_version_ 1782460822220439552
author Chatterjee, Susmita
Sarkar, Anupam
Rao, Krishna D.
author_facet Chatterjee, Susmita
Sarkar, Anupam
Rao, Krishna D.
author_sort Chatterjee, Susmita
collection PubMed
description BACKGROUND: Postpartum heammorrhage (PPH), defined as blood loss greater than or equal to 500 ml within 24 hours after birth, is the leading cause of maternal deaths globally and in India. Misoprostol is an important option for PPH management in setting where oxytocin (the gold standard for PPH prevention and treatment) in not available or not feasible to use. For the substantial number of deliveries which take place at home or at lower level heatlh facilities in India, misoprostol pills can be adminstered to prevent PPH. The standard approach using misoprostol is to administer it prophylactically as primary prevention (600 mcg). An alternative strategy could be to administer misoprostol only to those who are at high risk of having PPH i.e. as secondary prevention. METHODS: This study reports on the relative cost per person of a strategy involving primary versus secondary prevention of PPH using misoprostol. It is based on a randomized cluster trial that was conducted in Bijapur district in Karnataka, India between December 2011 and March 2014 among pregnant women to compare two community-level strategies for the prevention of PPH: primary and secondary. The analysis was conducted from the government perspective using an ingredient approach. RESULTS: The cluster trial showed that there were no significant differences in clinical outcomes between the two study arms. However, the results of the cost analysis show that there is a difference of INR 6 (US$ 0.1) per birth for implementing the strategies primary versus secondary prevention. In India where 14.9 million births take place at sub-centres and at home, this additional cost of INR 6 per birth translates to an additional cost of INR 94 (US$ 1.6) million to the government to implement the primary prevention compared to the secondary prevention strategy. CONCLUSION: As clinical outcomes did not differ significantly between the two arms in the trial, taking into account the difference in costs and potential issues with sustainability, secondary prevention might be a more strategic option.
format Online
Article
Text
id pubmed-5068696
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-50686962016-10-27 Using Misoprostol for Primary versus Secondary Prevention of Postpartum Haemorrhage – Do Costs Matter? Chatterjee, Susmita Sarkar, Anupam Rao, Krishna D. PLoS One Research Article BACKGROUND: Postpartum heammorrhage (PPH), defined as blood loss greater than or equal to 500 ml within 24 hours after birth, is the leading cause of maternal deaths globally and in India. Misoprostol is an important option for PPH management in setting where oxytocin (the gold standard for PPH prevention and treatment) in not available or not feasible to use. For the substantial number of deliveries which take place at home or at lower level heatlh facilities in India, misoprostol pills can be adminstered to prevent PPH. The standard approach using misoprostol is to administer it prophylactically as primary prevention (600 mcg). An alternative strategy could be to administer misoprostol only to those who are at high risk of having PPH i.e. as secondary prevention. METHODS: This study reports on the relative cost per person of a strategy involving primary versus secondary prevention of PPH using misoprostol. It is based on a randomized cluster trial that was conducted in Bijapur district in Karnataka, India between December 2011 and March 2014 among pregnant women to compare two community-level strategies for the prevention of PPH: primary and secondary. The analysis was conducted from the government perspective using an ingredient approach. RESULTS: The cluster trial showed that there were no significant differences in clinical outcomes between the two study arms. However, the results of the cost analysis show that there is a difference of INR 6 (US$ 0.1) per birth for implementing the strategies primary versus secondary prevention. In India where 14.9 million births take place at sub-centres and at home, this additional cost of INR 6 per birth translates to an additional cost of INR 94 (US$ 1.6) million to the government to implement the primary prevention compared to the secondary prevention strategy. CONCLUSION: As clinical outcomes did not differ significantly between the two arms in the trial, taking into account the difference in costs and potential issues with sustainability, secondary prevention might be a more strategic option. Public Library of Science 2016-10-18 /pmc/articles/PMC5068696/ /pubmed/27755601 http://dx.doi.org/10.1371/journal.pone.0164718 Text en © 2016 Chatterjee et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Chatterjee, Susmita
Sarkar, Anupam
Rao, Krishna D.
Using Misoprostol for Primary versus Secondary Prevention of Postpartum Haemorrhage – Do Costs Matter?
title Using Misoprostol for Primary versus Secondary Prevention of Postpartum Haemorrhage – Do Costs Matter?
title_full Using Misoprostol for Primary versus Secondary Prevention of Postpartum Haemorrhage – Do Costs Matter?
title_fullStr Using Misoprostol for Primary versus Secondary Prevention of Postpartum Haemorrhage – Do Costs Matter?
title_full_unstemmed Using Misoprostol for Primary versus Secondary Prevention of Postpartum Haemorrhage – Do Costs Matter?
title_short Using Misoprostol for Primary versus Secondary Prevention of Postpartum Haemorrhage – Do Costs Matter?
title_sort using misoprostol for primary versus secondary prevention of postpartum haemorrhage – do costs matter?
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5068696/
https://www.ncbi.nlm.nih.gov/pubmed/27755601
http://dx.doi.org/10.1371/journal.pone.0164718
work_keys_str_mv AT chatterjeesusmita usingmisoprostolforprimaryversussecondarypreventionofpostpartumhaemorrhagedocostsmatter
AT sarkaranupam usingmisoprostolforprimaryversussecondarypreventionofpostpartumhaemorrhagedocostsmatter
AT raokrishnad usingmisoprostolforprimaryversussecondarypreventionofpostpartumhaemorrhagedocostsmatter